Thrombin generation during reperfusion after coronary artery bypass surgery associates with postoperative myocardial damage

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 7, 2006, Pages 1523-1529

  Raivio, Peter ^a   Kuitunen, A ^a   Suojaranta Ylinen, R ^a   Lassila, R ^a,b   Petaja J ^c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b WIHURI RESEARCH INSTITUTE   (Finland)

^c JORVI HOSPITAL   (Finland)

Author keywords

Coronary artery disease; Myocardial revascularization; Reperfusion; Surgery; Thrombin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE MB; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTAMINE SULFATE; PROTHROMBIN; THROMBIN; TROPONIN T;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY REPERFUSION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ELECTIVE SURGERY; FEMALE; FIBRINOLYSIS; HEART HEMODYNAMICS; HEART INFARCTION; HEPARINIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; THROMBOGENESIS; TIME;

ADULT; AGED; AGED, 80 AND OVER; CORONARY ARTERY BYPASS; FEMALE; FIBRIN; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; REPERFUSION INJURY; THROMBIN;

EID: 33745238065     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02028.x     Document Type: Article

References (23)

1. Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003; 1: 1343-8.
2. 1+2 Thromb Haemost 1993; 70: 253-8.
3. Petäjä J, Pesonen E, Fernandez JA, Vento AE, Rämö OJ, Griffin JH. Cardiopulmonary bypass and activation of antithrombotic plasma protein C. J Thorac Cardiovasc Surg 1999; 118: 422-9.
4. Chandler WL, Velan T. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood 2003; 101: 4355-62.
5. Erlich JH, Boyle EM, Labriola J, Kovacich JC, Santucci RA, Fearns C, Morgan EN, Yun W, Luther T, Kojikawa O, Martin TR, Pohlman TH, Verrier ED, Mackman N. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 2000; 157: 1849-62.
6. Jormalainen M, Vento AE, Wartiovaara-Kautto U, Suojaranta-Ylinen R, Rämö OJ, Petäjä J. Recombinant hirudin enhances cardiac output and decreases systemic vascular resistance during reperfusion after cardiopulmonary bypass in a porcine model. J Thorac Cardiovasc Surg 2004; 128: 189-96.
7. Nilsson J, Algotsson L, Hoglund P, Luhrs C, Brandt J. Early mortality in coronary bypass surgery: The EuroSCORE versus The Society of Thoracic Surgeons risk algorithm. Ann Thorac Surg 2004; 77: 1235-9.
8. The Joint European Society of Cardiology and American College of Cardiology Committee. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-13.
9. Despotis GJ, Joist JH, Hogue Jr CW, Alsoufiev A, Joiner-Maier D, Santoro SA, Spitznagel E, Weitz JI, Goodnough LT. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76: 902-8.
10. Slaughter TF, LeBleu TH, Douglas Jr JM, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994; 80: 520-6.
11. Knudsen L, Hasenkam JM, Kure HH, Hughes P, Bellaiche L, Ahlburg P, Djurhuus C. Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass surgery. Thromb Res 1996; 84: 45-54.
12. Despotis GJ, Joist JH, Hogue Jr CW, Alsoufiev A, Kater K, Goodnough LT, Santoro SA, Spitznagel E, Rosenblum M, Lappas DG. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995; 110: 46-54.
13. Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC. Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol 2004; 24: 41-53.
14. Patterson C, Stouffer GA, Madamanchi N, Runge MS. New tricks for old dogs: Nonthrombotic effects of thrombin in vessel wall biology. Circ Res 2001; 88: 987-97.
15. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/ reperfusion. Circulation 1997; 96: 2302-10.
16. Schoots IG, Levi M, van Vliet AK, Maas AM, Roossink EH, van Gulik TM. Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats. Crit Care Med 2004; 32: 1375-83.
17. Yamaguchi Y, Hisama N, Okajima K, Uchiba M, Murakami K, Takahashi Y, Yamada S, Mori K, Ogawa M. Pretreatment with activated protein C or active human urinary thrombomodulin attenuates the production of cytokine-induced neutrophil chemoattractant following ischemia/ reperfusion in rat liver. Hepatology 1997; 25: 1136-40.
18. Laws KH, Clanton JA, Starnes VA, Lupinetti FM, Collins JC, Oates JA, Hammon Jr JW. Kinetics and imaging of indium-11-labeled autologous platelets in experimental myocardial infarction. Circulation 1983; 67: 110-6.
19. Mirabet M, Garcia-Dorado D, Inserte J, Barrabes JA, Lidon RM, Soriano B, Azevedo M, Padilla F, Agullo M, Ruiz-Meana M, Massaguer A, Pizcueta P, Soler-Soler J. Platelets activated by transient coronary occlusion exacerbate ischemia-reperfusion injury in rat hearts. Am J Physiol-Heart Circ Physiol 2002; 283: H1134-41.
20. Klatte K, Chaitman BR, Theroux P, Gavard JA, Stocke K, Boyce S, Bartels C, Keller B, Jessel A, GUARDIAN Investigators (The GUARD during Ischemia Against Necrosis). Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: Results from the GUARDIAN trial. J Am Coll Cardiol 2001; 38: 1070-7.
21. Costa MA, Carere RG, Lichtenstein SV, Foley DP, de Valk V, Lindenboom W, Roose PC, van Geldorp TR, Macaya C, Castanon JL, Fernandez-Avilez F, Gonzales JH, Heyer G, Unger F, Serruys PW. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation 2001; 104: 2689-93.
22. Kathiresan S, Servoss SJ, Newell JB, Trani D, MacGillivray TE, Lewandrowski K, Lee-Lewandrowski E, Januzzi Jr JL. Cardiac troponin T elevation after coronary artery bypass grafting is associated with increased one-year mortality. Am J Cardiol 2004; 94: 879-81.
23. Januzzi JL, Lewandrowski K, MacGillivray TE, Newell JB, Kathiresan S, Servoss SJ, Lee-Lewandrowski E. A comparison of cardiac troponin T and creatine kinase-MB for patient evaluation after cardiac surgery. J Am Coll Cardiol 2002; 39: 1518-23.